Welcome to our dedicated page for Retractable Tech SEC filings (Ticker: RVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Retractable Technologies, Inc. (RVP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Retractable’s filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports, describe its business of manufacturing and marketing VanishPoint®, EasyPoint®, and Patient Safe® safety medical products, as well as key financial and operational details.
In its periodic reports, Retractable discusses net sales, operating income or loss, domestic and international revenue mix, and the influence of product mix between VanishPoint® syringes and EasyPoint® needles on average selling prices and margins. The filings also address the material impact of tariffs on needles, syringes, and other products imported from China, and explain how these costs are reflected in cost of manufactured product. Disclosures describe the company’s efforts to increase U.S.-based manufacturing, adapt equipment for domestic production, and adjust its workforce in response to tariff pressures.
Form 8-K current reports for RVP document material events such as quarterly and annual results announcements, preferred stock dividend declarations for Series II Class B and Series III Class B Convertible Preferred Stock, workforce reductions, and product-related recognitions. These filings confirm that Retractable’s common stock is registered on NYSE American under the symbol RVP and that the company is incorporated in Texas.
On Stock Titan, users can review these SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as discussions of tariffs, product mix, liquidity considerations, and risk factors related to patent protection, supplier relationships, foreign trade risk, access to markets, production costs, and competition from larger safety device providers. The platform also surfaces updates in near real time as new filings are posted to EDGAR, helping users quickly see changes in Retractable’s reported results, capital structure, or material events.
By combining the full text of RVP’s SEC filings with AI-generated explanations, this page is intended to make it easier to understand how Retractable’s safety medical device business, financial performance, and risk disclosures are presented in its official regulatory documents.
Thomas J. Shaw, President & CEO, Director and 10% owner of Retractable Technologies (RVP), reported an acquisition of 2,100 common shares on 08/11/2025 under a Rule 10b5-1 plan at a weighted average price of $0.8118. After this transaction he beneficially owns 15,580,854 shares directly and 831,600 shares indirectly. The filing explains the indirect holdings include investment power over 500,000 shares as Trustee and voting control over the remainder pursuant to a voting agreement. The Rule 10b5-1 plan was adopted on August 22, 2024.
Thomas J. Shaw, President, CEO, Director and reported 10% owner of Retractable Technologies, Inc. (RVP), reported a transaction dated 08/07/2025 showing an acquisition of 49,541 shares of common stock at a weighted average price of $0.747. Following the reported transaction, the filing lists 15,578,754 shares beneficially owned directly and 831,600 shares beneficially owned indirectly.
The filing explains Mr. Shaw has investment power over 500,000 shares as trustee for a family member and retains voting control over the remainder under a voting agreement. The remarks note a Rule 10b5-1 plan adoption date of August 22, 2024. The form is signed by an attorney-in-fact on 08/11/2025.
Retractable Technologies (RVP) filed a Form 4 showing that President, CEO, Director and 10% owner Thomas J. Shaw bought 1,575 common shares on 08/01/2025 at a weighted-average price of $0.703. The transaction was coded “P” (open-market purchase) and executed under a Rule 10b5-1 plan adopted 08/22/2024.
Following the purchase, Shaw directly owns 15,498,332 shares and holds indirect control over an additional 831,600 shares—bringing his total beneficial interest to roughly 16.3 million shares. The incremental buy represents less than 0.01% of his existing stake, so economic impact is minimal, yet the action reiterates insider alignment at a depressed price level. No derivative security activity was reported.